{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:29:42Z","timestamp":1791887382042,"version":"4.3.4"},"reference-count":155,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005075","name":"Universitair Medisch Centrum Groningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["pharmrev.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reviews"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1124\/pharmrev.123.001045","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T17:40:17Z","timestamp":1726854017000},"page":"100002","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Emerging pharmacotherapies for obesity: A systematic review"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0027-5659","authenticated-orcid":false,"given":"Michail","family":"Kokkorakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Chakhtoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caline","family":"Rhayem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Al Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malak","family":"Ghezzawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valenzuela-Vallejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/pharmrev.123.001045_bib1","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cgh.2016.10.023","article-title":"White paper AGA: POWER - practice guide on obesity and weight management, education, and resources","volume":"15","author":"Acosta","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1124\/pharmrev.123.001045_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"key":"10.1124\/pharmrev.123.001045_bib3","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"issue":"Suppl 2","key":"10.1124\/pharmrev.123.001045_bib4","first-page":"S41","article-title":"Expert panel report: guidelines (2013) for the management of overweight and obesity in adults","volume":"22","year":"2014","journal-title":"Obesity (Silver Spring)"},{"issue":"Supplement_1","key":"10.1124\/pharmrev.123.001045_bib5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.2337\/dc24-SREV","article-title":"Summary of revisions: standards of care in diabetes-2024","volume":"47","year":"2024","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.123.001045_bib6","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1210\/endrev\/bnae011","article-title":"Relative energy deficiency in sport (REDs): endocrine manifestations, pathophysiology and treatments","volume":"45","author":"Angelidi","year":"2024","journal-title":"Endocr Rev"},{"key":"10.1124\/pharmrev.123.001045_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41574-024-00979-9","article-title":"Targeting the incretin system in obesity and type 2 diabetes mellitus","volume":"20","author":"Ansari","year":"2024","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib8","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: an endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/157015912799362788","article-title":"Sibutramine effects on central mechanisms regulating energy homeostasis","volume":"10","author":"Ara\u00fajo","year":"2012","journal-title":"Curr Neuropharmacol"},{"key":"10.1124\/pharmrev.123.001045_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.123.001045_bib11","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1172\/JCI78371","article-title":"Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight","volume":"124","author":"Baggio","year":"2014","journal-title":"J\u00a0Clin Invest"},{"key":"10.1124\/pharmrev.123.001045_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"10.1124\/pharmrev.123.001045_bib13","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/oby.22764","article-title":"Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity","volume":"28","author":"Bays","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/pharmrev.123.001045_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/oby.20663","article-title":"Canagliflozin: effects in overweight and obese subjects without diabetes mellitus","volume":"22","author":"Bays","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/pharmrev.123.001045_bib15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"key":"10.1124\/pharmrev.123.001045_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155722","article-title":"Recent research advances in metabolism, clinical and experimental","volume":"149","author":"Boutari","year":"2023","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A\u00a02022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib19","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin - its role in the homeostatic and\u00a0hedonic control of eating and recent developments of amylin analogs to\u00a0treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111675","article-title":"Incretin-based investigational therapies for the treatment of MASLD\/MASH","volume":"211","author":"Brouwers","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/pharmrev.123.001045_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9185987","article-title":"A\u00a0combination of leucine, metformin, and sildenafil treats nonalcoholic fatty liver disease and steatohepatitis in mice","volume":"2016","author":"Bruckbauer","year":"2016","journal-title":"Int J Hepatol"},{"key":"10.1124\/pharmrev.123.001045_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089166","article-title":"Synergistic effects of polyphenols and methylxanthines with leucine on AMPK\/Sirtuin-mediated metabolism in muscle cells and adipocytes","volume":"9","author":"Bruckbauer","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.001045_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/MED.0000000000000192","article-title":"Obesity medications: what does the future look like?","volume":"22","author":"Butsch","year":"2015","journal-title":"Curr Opin\u00a0Endocrinol Diabetes Obes"},{"key":"10.1124\/pharmrev.123.001045_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101882","article-title":"Pharmacotherapy of obesity: an update on the available medications and drugs under investigation","volume":"58","author":"Chakhtoura","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1124\/pharmrev.123.001045_bib27","article-title":"Drugs in the Pipeline for the Management of Obesity: A Systematic Review","author":"Chakhtoura","year":"2023","journal-title":"PROSPERO 2023 CRD42023428157"},{"key":"10.1124\/pharmrev.123.001045_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155531","article-title":"Advances in physiology, design and\u00a0development of novel medications changing the landscape of obesity pharmacotherapy","volume":"142","author":"Chakhtoura","year":"2023","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib29","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.2147\/DDDT.S365416","article-title":"Clinical insight on semaglutide for chronic weight management in adults: patient selection and special considerations","volume":"16","author":"Chao","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.123.001045_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1756285615578406","article-title":"A\u00a0review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures","volume":"8","author":"Chung","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1124\/pharmrev.123.001045_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.868037","article-title":"Is glucagon receptor activation the thermogenic solution for treating obesity?","volume":"13","author":"Concei\u00e7\u00e3o-Furber","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1124\/pharmrev.123.001045_bib32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1001\/jama.2024.6586","article-title":"Is weight loss-induced muscle mass loss\u00a0clinically relevant?","volume":"332","author":"Conte","year":"2024","journal-title":"JAMA"},{"issue":"15 Suppl","key":"10.1124\/pharmrev.123.001045_bib33","first-page":"S288","article-title":"A\u00a0review of current guidelines for the treatment of obesity","volume":"28","author":"Cornier","year":"2022","journal-title":"Am\u00a0J\u00a0Manag Care"},{"key":"10.1124\/pharmrev.123.001045_bib34","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab"},{"key":"10.1124\/pharmrev.123.001045_bib35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.pharmthera.2014.10.003","article-title":"PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer","volume":"147","author":"Das","year":"2015","journal-title":"Pharmacol Ther"},{"key":"10.1124\/pharmrev.123.001045_bib36","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1007\/s00125-010-1684-1","article-title":"Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009","volume":"53","author":"DeFronzo","year":"2010","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.123.001045_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000496183","article-title":"European practical and patient-centred guidelines for adult obesity management in primary care","volume":"12","author":"Durrer Schutz","year":"2019","journal-title":"Obes Facts"},{"key":"10.1124\/pharmrev.123.001045_bib38","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.soard.2022.08.013","article-title":"2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery","volume":"18","author":"Eisenberg","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1124\/pharmrev.123.001045_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11695-022-06332-1","article-title":"2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) indications for metabolic and bariatric surgery","volume":"33","author":"Eisenberg","year":"2023","journal-title":"Obes Surg"},{"key":"10.1124\/pharmrev.123.001045_bib40","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.001045_bib41","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A\u00a0rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.123.001045_bib42","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12933-021-01412-5","article-title":"The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect","volume":"20","author":"Fisman","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/pharmrev.123.001045_bib43","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","article-title":"Efficacy and safety of co-administered once-weekly cagrilintide 2\u00b74 mg with once-weekly semaglutide 2\u00b74 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","volume":"402","author":"Frias","year":"2023","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.001045_bib44","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ajcn\/66.2.267","article-title":"Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in\u00a0vitro and ex\u00a0vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice","volume":"66","author":"Fuhrman","year":"1997","journal-title":"Am J Clin Nutr"},{"key":"10.1124\/pharmrev.123.001045_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.645507","article-title":"Clinical perspectives on the use of subcutaneous and oral formulations of semaglutide","volume":"12","author":"Gallwitz","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1124\/pharmrev.123.001045_bib46","doi-asserted-by":"crossref","first-page":"e1339","DOI":"10.1210\/clinem\/dgab848","article-title":"New horizons. A new paradigm for treating to target with second-generation obesity medications","volume":"107","author":"Garvey","year":"2022","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"Suppl 3","key":"10.1124\/pharmrev.123.001045_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.1124\/pharmrev.123.001045_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170183","article-title":"Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists","volume":"125","author":"Gasbjerg","year":"2020","journal-title":"Peptides"},{"key":"10.1124\/pharmrev.123.001045_bib49","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.3748\/wjg.v25.i32.4567","article-title":"New era: endoscopic treatment options in obesity-a paradigm shift","volume":"25","author":"Glass","year":"2019","journal-title":"World J Gastroenterol"},{"key":"10.1124\/pharmrev.123.001045_bib50","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ijo.2017.287","article-title":"US health policy and prescription drug coverage of FDA-approved medications for the treatment of obesity","volume":"42","author":"Gomez","year":"2018","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pharmrev.123.001045_bib51","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S2213-8587(16)30162-0","article-title":"Association of the\u00a0magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial","volume":"4","author":"Gregg","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib52","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1053\/j.gastro.2022.08.045","article-title":"AGA clinical practice guideline on pharmacological interventions for adults with obesity","volume":"163","author":"Grunvald","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1124\/pharmrev.123.001045_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2023.101762","article-title":"Discovery of ecnoglutide - a novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog","volume":"75","author":"Guo","year":"2023","journal-title":"Mol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib54","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/ph3082398","article-title":"Combinations of drugs in the treatment of obesity","volume":"3","author":"Halpern","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1124\/pharmrev.123.001045_bib55","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41574-022-00783-3","article-title":"Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1","volume":"19","author":"Hammoud","year":"2023","journal-title":"Nat Rev Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib56","article-title":"Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus","volume":"57","author":"Hare","year":"2010","journal-title":"Dan Med Bull"},{"key":"10.1124\/pharmrev.123.001045_bib57","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.6221","article-title":"Semaglutide vs endoscopic sleeve gastroplasty for weight loss","volume":"7","author":"Haseeb","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1124\/pharmrev.123.001045_bib58","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/dbi21-0004","article-title":"The role of GIP in the regulation of GLP-1 satiety and nausea","volume":"70","author":"Hayes","year":"2021","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.123.001045_bib59","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/dom.13654","article-title":"The effects of licogliflozin, a dual SGLT1\/2 inhibitor, on body weight in obese patients with or without diabetes","volume":"21","author":"He","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"H\u00f8jberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.123.001045_bib61","doi-asserted-by":"crossref","first-page":"632","DOI":"10.2337\/dc16-2427","article-title":"Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial","volume":"40","author":"Hollander","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1124\/pharmrev.123.001045_bib62","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/osp4.405","article-title":"Effects of a novel combination of orlistat and acarbose on tolerability, appetite, and glucose metabolism in persons with obesity","volume":"6","author":"Holmb\u00e4ck","year":"2020","journal-title":"Obes Sci Pract"},{"key":"10.1124\/pharmrev.123.001045_bib63","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1002\/oby.23557","article-title":"Effects of a novel weight-loss combination product containing orlistat and acarbose on obesity: a randomized, placebo-controlled trial","volume":"30","author":"Holmb\u00e4ck","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/pharmrev.123.001045_bib64","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.peptides.2017.09.018","article-title":"Oxyntomodulin: actions and role in diabetes","volume":"100","author":"Holst","year":"2018","journal-title":"Peptides"},{"key":"10.1124\/pharmrev.123.001045_bib65","article-title":"Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss","volume":"3","author":"Hope","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1124\/pharmrev.123.001045_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.735019","article-title":"Striking the balance: GLP-1\/glucagon co-agonism as a treatment strategy for obesity","volume":"12","author":"Hope","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1124\/pharmrev.123.001045_bib67","series-title":"StatPearls [Internet]","article-title":"Setmelanotide","author":"Hussain","year":"2024"},{"key":"10.1124\/pharmrev.123.001045_bib68","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib69","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"25 Suppl 2","key":"10.1124\/pharmrev.123.001045_bib70","first-page":"S102","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and The Obesity Society","volume":"129","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.001045_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101691","article-title":"Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple-ascending-dose phase 1b trial","volume":"54","author":"Ji","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1124\/pharmrev.123.001045_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101088","article-title":"IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: a randomised, placebo-controlled, multiple ascending dose phase 1b study","volume":"39","author":"Ji","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1124\/pharmrev.123.001045_bib73","doi-asserted-by":"crossref","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","article-title":"A\u00a0phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity","volume":"14","author":"Ji","year":"2023","journal-title":"Nat Commun"},{"key":"10.1124\/pharmrev.123.001045_bib74","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3949\/ccjm.87a.19102","article-title":"Overcoming obesity: weight-loss drugs are underused","volume":"87","author":"Kanj","year":"2020","journal-title":"Cleve Clin J Med"},{"key":"10.1124\/pharmrev.123.001045_bib75","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2","volume":"53","author":"Kasichayanula","year":"2014","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/pharmrev.123.001045_bib76","article-title":"FDA\u2019s Challenge for Approval of Obesity Drugs: Navigating Between Scylla and Charybdis","author":"Kaul","year":"2012","journal-title":"American College of Cardiology"},{"key":"10.1124\/pharmrev.123.001045_bib77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.pop.2015.10.004","article-title":"Behavioral modification for the management of obesity","volume":"43","author":"Kelley","year":"2016","journal-title":"Prim Care"},{"key":"10.1124\/pharmrev.123.001045_bib78","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/dom.12457","article-title":"Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial","volume":"17","author":"Kim","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes - survodutide","volume":"207","author":"Klein","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/pharmrev.123.001045_bib80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.001045_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155835","article-title":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: trials, opportunities, and challenges","volume":"154","author":"Kokkorakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155689","article-title":"Milestones in the journey towards addressing obesity; past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery","volume":"148","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib84","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","volume":"76","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.123.001045_bib85","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s13679-023-00527-y","article-title":"Update on the obesity epidemic: after the sudden rise, is the upward trajectory beginning to flatten?","volume":"12","author":"Koliaki","year":"2023","journal-title":"Curr Obes Rep"},{"key":"10.1124\/pharmrev.123.001045_bib86","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib87","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ecl.2016.04.004","article-title":"Regarding obesity as a disease: evolving policies and their implications","volume":"45","author":"Kyle","year":"2016","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1124\/pharmrev.123.001045_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155326","article-title":"Body fatness associations with cancer: evidence from recent epidemiological studies and future directions","volume":"137","author":"Larsson","year":"2022","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib89","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.001045_bib90","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib91","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/dom.15407","article-title":"Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial","volume":"26","author":"Li","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib92","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib93","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0140-6736(24)01210-8","article-title":"Obesity in adults","volume":"404","author":"Lingvay","year":"2024","journal-title":"Lancet"},{"key":"10.1124\/pharmrev.123.001045_bib94","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa2114833","article-title":"Calorie restriction with or without time-restricted eating in weight loss","volume":"386","author":"Liu","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/dom.12779","article-title":"Dapagliflozin once-daily and exenatide once-weekly dual therapy: a 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes","volume":"19","author":"Lundkvist","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib96","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1159\/000530395","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in nondiabetic patients with chronic kidney disease: a review of recent evidence","volume":"9","author":"Lv","year":"2023","journal-title":"Kidney Dis (Basel)"},{"key":"10.1124\/pharmrev.123.001045_bib97","series-title":"StatPearls [Internet]","article-title":"Acarbose","author":"McIver","year":"2024"},{"key":"10.1124\/pharmrev.123.001045_bib98","article-title":"What is the pipeline for future medications for obesity?","author":"Melson","year":"2024","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pharmrev.123.001045_bib99","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pr.117.014803","article-title":"Anti-obesity therapy: from rainbow pills to polyagonists","volume":"70","author":"M\u00fcller","year":"2018","journal-title":"Pharmacol Rev"},{"key":"10.1124\/pharmrev.123.001045_bib100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12933-023-01738-2","article-title":"Efficacy of cardiometabolic drugs in reduction of epicardial adipose tissue: a systematic review and meta-analysis","volume":"22","author":"Myasoedova","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1124\/pharmrev.123.001045_bib101","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-64-5-896","article-title":"Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency","volume":"64","author":"Nair","year":"1987","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib102","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02427280","article-title":"Reduced incretin effect in type 2 (non-insulin-dependent) diabetes","volume":"29","author":"Nauck","year":"1986","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.123.001045_bib103","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1210\/jcem-63-2-492","article-title":"Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses","volume":"63","author":"Nauck","year":"1986","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib152","doi-asserted-by":"crossref","DOI":"10.5888\/pcd14.160438","article-title":"Cardiometabolic risk factors among 1.3 million adults with overweight or obesity, but not diabetes, in 10 geographically diverse regions of the United States, 2012-2013","volume":"14","author":"Nichols","year":"2017","journal-title":"Prev Chronic Dis"},{"key":"10.1124\/pharmrev.123.001045_bib153","article-title":"Wegovy\u00ae semaglutide injection 2.4 mg","year":"2021","journal-title":"Novo Nordisk\u00ae"},{"key":"10.1124\/pharmrev.123.001045_bib154","article-title":"Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: a systematic review and meta-analysis","volume":"2022","author":"Okati-Aliabad","year":"2022","journal-title":"J\u00a0Obes"},{"key":"10.1124\/pharmrev.123.001045_bib155","article-title":"Role of behavioral interventions in the management of obesity","volume":"13","author":"Olateju","year":"2021","journal-title":"Cureus"},{"key":"10.1124\/pharmrev.123.001045_bib156","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz047","article-title":"Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist","volume":"105","author":"Parker","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib157","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","article-title":"Narrative review of topiramate: clinical uses and pharmacological considerations","volume":"40","author":"Pearl","year":"2023","journal-title":"Adv Ther"},{"key":"10.1124\/pharmrev.123.001045_bib158","doi-asserted-by":"crossref","first-page":"3890","DOI":"10.1210\/jc.2018-01056","article-title":"Physiology of activins\/follistatins: associations with metabolic and anthropometric variables and response to exercise","volume":"103","author":"Perakakis","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib159","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"10.1124\/pharmrev.123.001045_bib160","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"10.1124\/pharmrev.123.001045_bib161","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1111\/dom.13824","article-title":"Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study","volume":"21","author":"Pratley","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib162","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib163","first-page":"397","article-title":"Was sind die Gr\u00fcnde der Patientenpr\u00e4ferenz? Vergleich von oraler und subkutaner Darreichungsform [What are the reasons for patient preference? A comparison between oral and subcutaneous administration]","volume":"150","author":"Quante","year":"2012","journal-title":"Z\u00a0Orthop Unfall"},{"key":"10.1124\/pharmrev.123.001045_bib164","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MJT.0000000000001303","article-title":"Leucine and sildenafil combination therapy reduces body weight and metformin enhances the effect at low dose: a randomized controlled trial","volume":"28","author":"Rebello","year":"2021","journal-title":"Am J Ther"},{"key":"10.1124\/pharmrev.123.001045_bib165","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","article-title":"The mechanisms of action of metformin","volume":"60","author":"Rena","year":"2017","journal-title":"Diabetologia"},{"key":"10.1124\/pharmrev.123.001045_bib166","series-title":"Endotext [Internet]","article-title":"Glucagon physiology","author":"Rix","year":"2000"},{"key":"10.1124\/pharmrev.123.001045_bib167","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2147\/DMSO.S351982","article-title":"The emerging role of dual GLP-1 and GIP receptor agonists in glycemic management and cardiovascular risk reduction","volume":"15","author":"Rizvi","year":"2022","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.1124\/pharmrev.123.001045_bib168","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A\u00a0phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-G\u00f3mez","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1124\/pharmrev.123.001045_bib169","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.123.001045_bib170","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.regpep.2007.02.006","article-title":"GIP receptor mRNA expression in different fat tissue depots in postmenopausal non-diabetic women","volume":"142","author":"Rudovich","year":"2007","journal-title":"Regul Pept"},{"key":"10.1124\/pharmrev.123.001045_bib171","doi-asserted-by":"crossref","first-page":"10730","DOI":"10.1073\/pnas.162349799","article-title":"Adipose tissue mass can be regulated through the vasculature","volume":"99","author":"Rupnick","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/pharmrev.123.001045_bib172","doi-asserted-by":"crossref","first-page":"196","DOI":"10.7570\/jomes21033","article-title":"Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice?","volume":"30","author":"Ryan","year":"2021","journal-title":"J\u00a0Obes Metab Syndr"},{"key":"10.1124\/pharmrev.123.001045_bib173","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/164_2021_560","article-title":"Drugs for treating obesity","volume":"274","author":"Ryan","year":"2022","journal-title":"Handb Exp Pharmacol"},{"key":"10.1124\/pharmrev.123.001045_bib174","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"key":"10.1124\/pharmrev.123.001045_bib175","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: differences at 5%, 10%, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"key":"10.1124\/pharmrev.123.001045_bib176","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/dom.12585","article-title":"Glucagon increases energy expenditure independently of brown adipose tissue activation in humans","volume":"18","author":"Salem","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib177","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"10.1124\/pharmrev.123.001045_bib178","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41575-023-00888-8","article-title":"Hepatic glucose metabolism in the steatotic liver","volume":"21","author":"Scoditti","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"10.1124\/pharmrev.123.001045_bib179","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s11606-016-3949-y","article-title":"Pharmacotherapy for weight management in the VHA","volume":"32","author":"Semla","year":"2017","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1124\/pharmrev.123.001045_bib180","series-title":"LiverTox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2012"},{"key":"10.1124\/pharmrev.123.001045_bib181","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264974","article-title":"Preclinical evaluation of a protracted GLP-1\/glucagon receptor co-agonist: translational difficulties and pitfalls","volume":"17","author":"Simonsen","year":"2022","journal-title":"PLoS One"},{"key":"10.1124\/pharmrev.123.001045_bib182","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s13679-018-0300-4","article-title":"Future pharmacotherapy for obesity: new anti-obesity drugs on the horizon","volume":"7","author":"Srivastava","year":"2018","journal-title":"Curr Obes Rep"},{"key":"10.1124\/pharmrev.123.001045_bib183","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/dom.13661","article-title":"Intranasal glucagon acutely increases energy expenditure without inducing hyperglycaemia in overweight\/obese adults","volume":"21","author":"Stahel","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.156057","article-title":"The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation","volume":"161","author":"Stefanakis","year":"2024","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib184","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.mehy.2015.10.029","article-title":"Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia","volume":"86","author":"Suppli","year":"2016","journal-title":"Med Hypotheses"},{"key":"10.1124\/pharmrev.123.001045_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155744","article-title":"Rising global burden of cancer attributable to high BMI from 2010 to 2019","volume":"152","author":"Tan","year":"2024","journal-title":"Metabolism"},{"key":"10.1124\/pharmrev.123.001045_bib186","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.123.001045_bib187","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12916-015-0323-6","article-title":"Successful behavior change in obesity interventions in adults: a systematic review of self-regulation mediators","volume":"13","author":"Teixeira","year":"2015","journal-title":"BMC Med"},{"key":"10.1124\/pharmrev.123.001045_bib188","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mcna.2017.08.004","article-title":"Obesity as a disease","volume":"102","author":"Upadhyay","year":"2018","journal-title":"Med Clin North Am"},{"key":"10.1124\/pharmrev.123.001045_bib189","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/JOE-13-0414","article-title":"Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS","volume":"221","author":"van Bloemendaal","year":"2014","journal-title":"J\u00a0Endocrinol"},{"key":"10.1124\/pharmrev.123.001045_bib190","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A\u00a0GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat Metab"},{"key":"10.1124\/pharmrev.123.001045_bib191","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.eplepsyres.2011.05.014","article-title":"Topiramate-induced weight loss: a review","volume":"95","author":"Verrotti","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1124\/pharmrev.123.001045_bib192","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/amp0000517","article-title":"Lifestyle modification approaches for the treatment of obesity in adults","volume":"75","author":"Wadden","year":"2020","journal-title":"Am Psychol"},{"key":"10.1124\/pharmrev.123.001045_bib193","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib195","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/pharmrev.123.001045_bib196","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"key":"10.1124\/pharmrev.123.001045_bib197","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: a clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"CMAJ"},{"key":"10.1124\/pharmrev.123.001045_bib198","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/pharmrev.123.001045_bib199","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1002\/oby.21914","article-title":"Fifty years of behavioral\/lifestyle interventions for overweight and obesity: where have we been and where are we going?","volume":"25","author":"Williamson","year":"2017","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/pharmrev.123.001045_bib200","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1038\/sj.ijo.0803344","article-title":"Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial","volume":"30","author":"Wynne","year":"2006","journal-title":"Int J Obes (Lond)"},{"key":"10.1124\/pharmrev.123.001045_bib201","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.2337\/diabetes.54.8.2390","article-title":"Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial","volume":"54","author":"Wynne","year":"2005","journal-title":"Diabetes"},{"key":"10.1124\/pharmrev.123.001045_bib202","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2021.9486","article-title":"Progress in pharmacotherapy for obesity","volume":"326","author":"Yanovski","year":"2021","journal-title":"JAMA"},{"key":"10.1124\/pharmrev.123.001045_bib203","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/bcpt.13427","article-title":"Central control of energy balance by amylin and calcitonin receptor agonists and their potential for treatment of metabolic diseases","volume":"127","author":"Zakariassen","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1124\/pharmrev.123.001045_bib205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2147\/DDDT.S385981","article-title":"Review on the diverse biological effects of glabridin","volume":"17","author":"Zhang","year":"2023","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/pharmrev.123.001045_bib206","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.706914","article-title":"Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis","volume":"12","author":"Zheng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Pharmacological Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0031699724000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/pharmrev.123.001045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T12:26:17Z","timestamp":1750940777000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0031699724000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":155,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0031699724000024"],"URL":"https:\/\/doi.org\/10.1124\/pharmrev.123.001045","relation":{},"ISSN":["0031-6997"],"issn-type":[{"value":"0031-6997","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging pharmacotherapies for obesity: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/pharmrev.123.001045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100002"}}